Copyright
©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. Oct 28, 2005; 11(40): 6381-6384
Published online Oct 28, 2005. doi: 10.3748/wjg.v11.i40.6381
Published online Oct 28, 2005. doi: 10.3748/wjg.v11.i40.6381
Table 2 Effects of nucleosides on the cell cycle progression, caspas-3 activity and sFas-L content in HepG2 cells1
Treatment | Control | Inosine | Cytidine | Uridine | Thymidine | Adenosine | Gaunosine |
SubG1 (%) | 2.6±0.8a | 3.2±0.3a | 6.9±0.2a | 6.5±1.5a | 26.8±2.3a | 9.6±1.5a | 5.7±1.2a |
G0/G1(%) | 67.7±1.1a | 69.2±0.1a | 74.1±1.3a | 84.8±2.6a | 54.4±1.8a | 64.8±1.4a | 68.0±1.9a |
S (%) | 15.7±0.0a | 18.8±0.3a | 8.5±0.2a | 3.1±0.3a | 12.0±0.2a | 10.6±0.4a | 17.3±0.7a |
G2/M (%) | 14.0±1.9a | 8.8±0.1a | 10.5±1.0a | 5.7±0.8a | 6.8±0.8a | 15.0±0.9a | 9.0±1.3a |
Caspase-3 (%)2 | 100±0a | 101±5a | 97±6a | 98±5a | 148±2a | 104±4a | 100±3a |
sFas-L (pg/mL) | 0.11±0.01a | 0.14±0.01a | 0.08±0.03a | 0.15±0.03a | 0.17±0.02a | 0.15±0.07a | 0.10±0.03a |
- Citation: Yang SC, Chiu CL, Huang CC, Chen JR. Apoptosis induced by nucleosides in the human hepatoma HepG2. World J Gastroenterol 2005; 11(40): 6381-6384
- URL: https://www.wjgnet.com/1007-9327/full/v11/i40/6381.htm
- DOI: https://dx.doi.org/10.3748/wjg.v11.i40.6381